Open access
Aug 2026
Longitudinal evaluation of health-related quality of life in Chinese patients with early-stage HER2-positive breast cancer undergoing neratinib extended adjuvant therapy: a real-world prospective cohort study
Background Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is a well-established extended adjuvant therapy for early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer. However, its clinical application is often constrained by the high incidence of treatment-related diarrhea. Th...
Xuanhua Liang, Zibai Guo, Jinhong Wei et al.
· Frontiers in Oncology · 0 citations